Unity Biotechnology with ticker code (UBX) now have 7 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The target price ranges between 12 and 4 with the average target price sitting at 6.86. With the stocks previous close at 4.18 this is indicating there is a potential upside of 64.1%. The day 50 moving average is 4.45 while the 200 day moving average is 5.81. The market cap for the company is $238m. Company Website: http://www.unitybiotechnology.com
Unity Biotechnology, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge and changed its name to Unity Biotechnology in January 2015. Unity Biotechnology was incorporated in 2009 and is headquartered in South San Francisco, California.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.
